Stockscreener 앱 받기
2.06
0.98%
0.02
전일 마감가:
$2.04
열려 있는:
$2.09
하루 거래량:
21,693
Relative Volume:
0.57
시가총액:
$23.84M
수익:
$3.35M
순이익/손실:
$86,000
주가수익비율:
133.77
EPS:
0.0154
순현금흐름:
$2.67M
1주 성능:
+3.00%
1개월 성능:
-9.25%
6개월 성능:
-7.62%
1년 성능:
+79.13%
1일 변동 폭
$2.02
$2.09
1주일 범위
$1.91
$2.09
52주 변동 폭
$0.99
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
명칭
Therapeuticsmd Inc
전화
561-961-1900
주소
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.06 | 23.61M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-07 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2020-05-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-02 | 개시 | Guggenheim | Buy |
| 2019-10-17 | 개시 | H.C. Wainwright | Buy |
| 2019-04-30 | 재개 | Noble Capital Markets | Outperform |
| 2018-06-15 | 개시 | JP Morgan | Overweight |
| 2017-09-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2017-07-11 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2017-05-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2016-11-22 | 재개 | Jefferies | Buy |
| 2016-11-22 | 개시 | Oppenheimer | Outperform |
| 2016-11-07 | 재개 | Guggenheim | Buy |
| 2016-04-04 | 개시 | Goldman | Buy |
| 2015-12-08 | 재확인 | Jefferies | Buy |
| 2015-12-08 | 재확인 | Stifel | Buy |
| 2015-09-21 | 재확인 | Jefferies | Buy |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2014-07-08 | 개시 | FBR Capital | Outperform |
| 2014-04-17 | 재확인 | Noble Financial | Buy |
| 2014-01-28 | 재확인 | Noble Financial | Buy |
모두보기
Therapeuticsmd Inc 주식(TXMD)의 최신 뉴스
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Ongoing ChallengesEarnings Call Highlights - DonanımHaber
TherapeuticsMD (TXMD) News Flow - Moomoo
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD (TXMD) Rallies 3.94% as Stock Approaches Key Resistance at $2.22Stop Run - dars.gov.et
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to earnings forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
Enterprise value to revenue forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
TherapeuticsMD Inc (TXMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc (TXMD) Institutional Confidence - TradingKey
TherapeuticsMD Inc (TXMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TXMD Q3 2023 Earnings: EPS Misses Estimates Amid Continued Cash BurnNet Income Trends - newsline.com
TherapeuticsMD (TXMD) Gains 3.64%, Tests Resistance at $2.39High Low Breadth - newsline.com
TXMD Q3 2023 Earnings: EPS Misses Estimates Sharply, Yet Stock Surges 20.9%EPS Surprise History - newsline.com
TXMD Q3 2023 Earnings: Wider-than-Expected Loss Highlights Operational ChallengesProfit Inflection Point - newsline.com
TherapeuticsMD (TXMD) Nears Support Amid Modest Selling PressureIndex Put Call - newsline.com
TherapeuticsMD Inc. (TXMD) Gains Ground as Shares Push Toward Resistance ZoneAAII Neutral - newsline.com
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Highlights Ongoing ChallengesEarnings Quality Score - dars.gov.et
TXMDTherapeuticsMD Inc Stock Price and Quote - Finviz
TXMD Q3 2023 Earnings: Deep EPS Miss Overshadowed by Strategic ProgressNegative Surprise Momentum - newsline.com
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Operational ChallengesTrough Earnings Signal - The Legal Advocate
TXMD Q3 2023 Earnings: Wider-Than-Expected Loss Amid Zero RevenuePositive Surprise Momentum - DonanımHaber
TXMD Q3 2023 Earnings: EPS Misses Estimates, Stock DeclinesPost-Earnings Drift - newsline.com
TXMD Q3 2023 Earnings: EPS Misses Estimates by Wide Margin Amidst Operational ChallengesSaaS Earnings Trends - dars.gov.et
TXMD Q3 2023 Earnings: A Significant EPS Miss Amid No Reported RevenueLow Growth Earnings - newsline.com
TherapeuticsMD (TXMD) Edges Higher as Support Holds Near $2.01Post-Earnings Moves - Newser
What TherapeuticsMD TXMD flagged as biggest challenges ahead Q3 2023 EPS Misses ViewsBanking Earnings Report - The Legal Advocate
TherapeuticsMD Announces First Quarter 2026 Financial Results - BioSpace
Therapeuticsmd Inc (TXMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.50%
0.79%
자본화:
|
볼륨(24시간):